1[1]Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J, 2000, 139:2-8.
2[2]Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol, 1999, 31: 949-970.
3[3]Wei C C, Meng Q C, Palmer R, et al. Evidence for angiotensin converting enzyme and chymase mediated angiotensin Ⅱ formation in the interstitial fluid space of the dog heart in vivo. Circulation, 1999, 99: 2583-2589.
4[4]Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin Ⅱ during ACE inhibition. J Cardiovasc Pharmacol, 1990, 15: 276-282.
5[5]Jalowy A, Szhulz R, Dorge H, et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykininand prostaglandins in pigs. J Am Coll Cardiol, 1998, 32: 1787-1796.
6[6]Siragy H M, Carey R M. The subtype 2 angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest, 1997,325:449-454.
7[7]Krombach R S, Clair M J, Hendrick J W, et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res, 1998, 38: 631-645.
8[8]Spinale F G, de Gasparo M, Whitebread S, et al.Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation, 1997, 96: 2385-2396.
9[9]Kim S, Zhan Y, Izumi Y, et al. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Hypertension, 2000, 35: 769-774.
10[10]Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation, 2001, 103: 148-154.
二级参考文献4
1Hamroff G,Blanfarb I,Mancini D,et al.Angiotensin Ⅱ receptor blockade further reduces afterload safely in patients maximally treated with angiotensin converting enzgme inhibitor for heart failure[].Journal of Cardiovascular Pharmacology.1997
2Olivetti G,Capasso JM,Meggs LG,et al.Cellular basis of chronic ventricular remodeling after myocardial infarction in rats[].Circulation Research.1991
3Blaufarb IS,Sonnenblick.The renin-angiotensin system in left ventricular remodeling[].The American Journal of Cardiology.1996
4Azizi M,Chatellier G,Guyene TT.Additive effects of combined angiotensin-converting enzgme inhibition and angiotensin II antagonist on blood pressure and renin release in sodium-depleted normentives[].Circulation.1995
4Carelock J, Clark AP. Heart failure : pathophysiologic mechanisms. Am J Nuts,2001,101(12) :26-33.
5The SOLVD Investigatiors. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med, 1992,327 (10) :685-691.
6Hant SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adulta report of the American college of cardiology/ American heart association task force on practice guidelines( writing committee to update the 2001 guidelines for the evaluation and management of heart failure) :developed in collaboration with the American college of chest physicians and international society for heart and lung transplantation:endorsed by the heart rhythm society. Circulation ,2005,112(12) : 154-235.
7McMurray JJ, Ostergreu J ;Swedberg K, et al. Effects ot candesartan in patients with chromic heart failure and reduced left-ventricular systdic function taking augiotensin-couvercdng-enzyme iuhibitors: the CHARM-Added trial. Lancet, 2003, 362 ( 9386 ):767-771.
8Mckelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOL VD pilot study investigators. Circulation, 1999,100(10) : 1056-1064.
9Mooser V, Nussberger J,Juillerat L, et al. Reactive hyper reninemia is a major determinant of plasma angiotensin Ⅱ during ACE inhibition[J]. J Cardiovasc Pharmacol,2004,15 276 - 282.
10Chobanian AV, Bakris GL, Black HR, et al. Roceelta EJ and the national high blood pressure education program coordinating committee. The seventh report of the joint national committee oil the prevention, detection, evaluation and treament of high blood pressure[J]. Hypertension, 2003,42:1206 - 1252.
